ALNYLAM PHARMACEUTICALS, INC. (ALNY) Total liabilities 2016–2025
ALNYLAM PHARMACEUTICALS, INC. (ALNY) total liabilities at each fiscal year-end, per SEC filings.
$4.2BFY2025 · since FY2016: $342.6M → $4.2B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $4.2B | +0.1% |
| FY2024 | $4.2B | +3.0% |
| FY2023 | $4.1B | +9.3% |
| FY2022 | $3.7B | +21.3% |
| FY2021 | $3.1B | +27.8% |
| FY2020 | $2.4B | +150.0% |
| FY2019 | $956.4M | +250.6% |
| FY2018 | $272.8M | +19.5% |
| FY2017 | $228.3M | -33.4% |
| FY2016 | $342.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice